We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Heavy Investments Dent H&R Block (HRB) in Q2 Earnings?
Read MoreHide Full Article
H&R Block, Inc. (HRB - Free Report) is scheduled to report second-quarter fiscal 2019 results on Dec 5, after the bell.
The company has an impressive earnings surprise history, surpassing the Zacks Consensus Estimate in all of the trailing four quarters with an average positive earnings surprise of 6.9%. Shares have gained 7.7% year to date, against the industry’s decline of 2.8%.
Let’s see how things are shaping up for the announcement.
Investments to Affect Quarterly Results
The Zacks Consensus Estimate for revenues in the to-be-reported quarter is pegged at $138 million, indicating year-over-year decline of 2.1%. The consensus mark for the bottom line is pegged at a loss of 92 cents, which indicates year-over-year rise of 29.6%. Ongoing strategic investments in price, technology and operations will continue to weigh on revenues and increase costs. This will negatively impact the company’s results in the to-be-reported quarter.
Seasonality to Have a Greater Impact
Seasonality might have a higher negative impact on the upcoming quarterly results compared with the year-ago quarter. The company generates majority of revenues and earns profit in the fourth quarter of the fiscal year, as most of its clients file their tax returns from January through April. Revenues stay significantly down and the company incurs loss in the first three quarters of the fiscal.
Our Model Does Not Suggest a Beat
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates if it also has a positive Earnings ESP. Zacks Rank #4 (Sell) or 5 (Strong Sell) stocks are best avoided, especially if they have a negative Earnings ESP. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
H&R Block has an Earnings ESP of 0.00% and a Zacks Rank #3, a combination that lowers chances of an earnings beat.
Stocks to Consider
Here are some stocks that you may want to consider as our model shows that these have the right combination of elements to deliver a positive earnings surprise:
Fiserv, Inc has an Earnings ESP of +0.84% and a Zacks Rank #3.
Waste Management, Inc (WM - Free Report) has an Earnings ESP of +0.70% and a Zacks Rank #3.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
Image: Bigstock
Will Heavy Investments Dent H&R Block (HRB) in Q2 Earnings?
H&R Block, Inc. (HRB - Free Report) is scheduled to report second-quarter fiscal 2019 results on Dec 5, after the bell.
The company has an impressive earnings surprise history, surpassing the Zacks Consensus Estimate in all of the trailing four quarters with an average positive earnings surprise of 6.9%. Shares have gained 7.7% year to date, against the industry’s decline of 2.8%.
Let’s see how things are shaping up for the announcement.
Investments to Affect Quarterly Results
The Zacks Consensus Estimate for revenues in the to-be-reported quarter is pegged at $138 million, indicating year-over-year decline of 2.1%. The consensus mark for the bottom line is pegged at a loss of 92 cents, which indicates year-over-year rise of 29.6%. Ongoing strategic investments in price, technology and operations will continue to weigh on revenues and increase costs. This will negatively impact the company’s results in the to-be-reported quarter.
Seasonality to Have a Greater Impact
Seasonality might have a higher negative impact on the upcoming quarterly results compared with the year-ago quarter. The company generates majority of revenues and earns profit in the fourth quarter of the fiscal year, as most of its clients file their tax returns from January through April. Revenues stay significantly down and the company incurs loss in the first three quarters of the fiscal.
Our Model Does Not Suggest a Beat
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates if it also has a positive Earnings ESP. Zacks Rank #4 (Sell) or 5 (Strong Sell) stocks are best avoided, especially if they have a negative Earnings ESP. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
H&R Block has an Earnings ESP of 0.00% and a Zacks Rank #3, a combination that lowers chances of an earnings beat.
Stocks to Consider
Here are some stocks that you may want to consider as our model shows that these have the right combination of elements to deliver a positive earnings surprise:
Automatic Data Processing, Inc (ADP - Free Report) has an Earnings ESP of +0.21% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Fiserv, Inc has an Earnings ESP of +0.84% and a Zacks Rank #3.
Waste Management, Inc (WM - Free Report) has an Earnings ESP of +0.70% and a Zacks Rank #3.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>